1
Sep
2020
Mood Disorder R&D, Lacking Innovation, Turns to Psychedelics
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Aug
2020
Antibiotic Resistance Looms Large in Pandemic; CRISPR Phages Show Promise
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
Jul
2020
Race and Life Sciences: Where is the Healing?
When I started to go to the J.P. Morgan Healthcare Conference, it was still known as H&Q after boutique bank Hambrecht & Quist that had originated it. This means that, as a journalist, I have been able to watch biopharma grow up over the last 20 years. Those first few events I attended had so little diversity that the upstairs... Read More
15
Jul
2020
Next-gen Synthetic Biology Pushes Further Into Drug Discovery, mRNA and DNA on the Desktop
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Jun
2020
DNA Sequencing Startups Aim to Reduce Cost, Increase Meaning in the Data
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Jun
2020
Complexity in Motion: Multi-Omics Tools Unravel Path From Genotype to Phenotype
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
May
2020
Biopharma Gets Serious, In a Hurry, About Virtual Clinical Trials
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
May
2020
Beyond CAR-T: New Engineered Immune Cell Types Head to the Clinic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
Mar
2020
Cancer Drugmakers Seek to Broaden Use of Tissue-Agnostic Therapies
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Mar
2020
Solid Tumors Have Eluded CAR-T, But Novel Targets and Techniques Are At Hand
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Feb
2020
Automation and Miniaturization Are Upon Us: Gritstone’s Mission to Make Personalized Medicines
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Jan
2020
HBV Curative Treatments Gear Up in the Clinic, as HCV Combos Help to Guide the Way
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Dec
2019
Biotechs Build on Single-cell Analytics for Drug R&D, as Human Cell Atlas is Mapped
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Nov
2019
New Gene-Editing Candidates Target Blood Disorders, as Gene Therapies Start to Hit the Market
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Oct
2019
Early Cancer Screening is Maturing. What Will It Mean for Drug Developers?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Aug
2019
Autoimmunity Research Paves the Way for New Ideas in Halting, Preventing Type 1 Diabetes
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Aug
2019
As CAR-T Ranks Expand, Industry Scrambles to Solve Long-Standing Manufacturing Challenges
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Jul
2019
CRISPR Boosts Animal Models, Making Preclinical Research More Efficient
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Jul
2019
As Cancer Immunotherapy Booms, Biomarkers Re-Emerge to Guide Treatment
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
31
May
2019
Organs-on-a-chip, Organoids Start to Deliver Results as an Alternative Preclinical Route
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.